Available Technology
Novel compositions which modulate iron uptake in cells for the treatment of iron deficient anemias or iron overload disorders
Technology:
Stimulator of Fe transport (SFT) - An iron transport protein to regulate cellular iron levels
Markets Addressed
The novel compositions of this invention provide pharmaceutical agents or can lead to the identification of pharmaceutical agents to regulate cellular iron levels for the treatment of iron deficient anemias or iron overload disorders. Both conditions are prevalent within our population. The gene for genetic hemochromatosis (iron overload) is the most prevalent mutant gene known within the human population. Iron deficiency is common in pregnant women, who are routinely treated with iron supplements.
Innovations and Advantages
Iron is an essential element for the growth and maintenance of animals and most microorganisms. This invention provides novel compositions which modulate iron uptake in cells. The DNA sequence of this novel transmembrane protein is unique, having only remote homology to other ion transport proteins. The predicted transmembrane places this protein within the ABC-cassette transporter superfamily which also includes the CFTR (cystic fibrosis) gene and MDR (multi-drug resistance) gene. Its presence in all cell types analyzed suggests that this novel iron transporter is an essential component in the process of cellular iron transfer.
Additional Information
Intellectual Property Status: Issued U.S. patent nos.: 5,780,264
Tweet
Inventor(s):
Gutierrez, Jesus
Wessling-Resnick, Marianne
Categories:
For further information, please contact:
Debra Peattie, Director of Business Development
(617) 495-3067
Reference Harvard Case #1248